文献速递泌尿系结石

抗凝或抗血小板治疗患者输尿管软镜实践模式与结局

Ureteroscopy in Patients Taking Anticoagulant or Antiplatelet Therapy: Practice Patterns and Outcomes in a Surgical Collaborative.
PubMed 文献 · J Urol · 2020-10-09

基于MUSIC注册表2016-2019年31家机构9982例输尿管软镜病例,抗凝治疗占3.1%、抗血小板治疗占7.8%。抗凝或抗血小板治疗与急诊就诊无关,但抗血小板治疗显著增加住院风险(OR 1.48,95%CI 1.02-2.14);输尿管通道鞘使用率在机构间差异大(23%-100%),且与抗凝/抗血小板治疗无关。

要点

  • 抗凝治疗患者行输尿管软镜安全,不增加急诊就诊风险。
  • 抗血小板治疗与住院风险显著增加相关(OR 1.48,95%CI 1.02-2.14)。
  • 各机构及术者间对接受抗凝/抗血小板治疗患者行输尿管软镜的比例差异显著。

核心结论

  • 抗凝治疗患者行输尿管软镜安全,但抗血小板治疗增加住院风险。
  • 尽管指南推荐,输尿管通道鞘使用与抗凝/抗血小板治疗状态无关。

研究设计与样本

  • 基于密歇根泌尿外科手术改进协作组(MUSIC)临床注册表的回顾性研究。
  • 纳入2016年至2019年间31家机构的9982例输尿管软镜病例。

主要发现

  • 抗凝治疗占3.1%,抗血小板治疗占7.8%。
  • 抗凝或抗血小板治疗与急诊就诊无显著关联。
  • 住院率:抗凝组4.3%、抗血小板组5.5%、对照组3.2%;抗血小板治疗显著增加住院风险(OR 1.48,95%CI 1.02-2.14)。
  • 机构水平输尿管通道鞘使用率差异大(23%至100%),且与抗凝/抗血小板治疗无关。
  • 执行输尿管软镜的比例在机构间(0%至21%)和术者间(0%至35%)存在差异,与手术量无关。

关键数值与推荐

  • AUA指南推荐输尿管软镜作为抗凝或抗血小板治疗患者的一线治疗,并提倡使用输尿管通道鞘。

临床怎么用

  • 对抗血小板治疗患者行输尿管软镜需警惕住院风险增加。
  • 抗凝治疗患者行输尿管软镜总体安全,但仍需个体化评估。
  • 输尿管通道鞘使用率在不同机构间差异大,应关注指南依从性。

局限性

  • 无法根据抗凝/抗血小板药物的类型或剂量进行风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: AUA guidelines recommend ureteroscopy as first line therapy for patients on anticoagulant or antiplatelet therapy and advocate using a ureteral access sheath. We examined practice patterns and unplanned health care use for these patients in Michigan. MATERIALS AND METHODS: Using the Michigan Urological Surgery Improvement Collaborative (MUSIC) clinical registry we identified ureteroscopy cases from 2016 to 2019. We assessed outcomes and adherence to guidelines based on therapy at time of ureteroscopy: 1) anticoagulant: continuous warfarin or novel oral agent therapy; 2) antiplatelet: continuous clopidogrel or aspirin therapy; 3) control: not on anticoagulant/antiplatelet therapy. We fit multivariate models to assess anticoagulant or antiplatelet therapy association with emergency department visits, hospitalization and ureteral access sheath use. RESULTS: In total, 9,982 ureteroscopies were performed across 31 practices with 3.1% and 7.8% on anticoagulant and antiplatelet therapy, respectively. There were practice (0% to 21%) and surgeon (0% to 35%) variations in performing ureteroscopy on patients on anticoagulant/antiplatelet therapy regardless of volume. After adjusting for risk factors, anticoagulant or antiplatelet therapy was not associated with emergency department visits. Hospitalization rates in anticoagulant, antiplatelet and control groups were 4.3%, 5.5% and 3.2%, respectively, and significantly increased with antiplatelet therapy (OR 1.48, 95% CI 1.02-2.14). Practice-level ureteral access sheath use varied (23% to 100%) and was not associated with anticoagulant/antiplatelet therapy. Limitations include inability to risk stratify between type/dosage of anticoagulant/antiplatelet therapy. CONCLUSIONS: We found practice-level and surgeon-level variation in performing ureteroscopy while on anticoagulant/antiplatelet therapy. Ureteroscopy on anticoagulant is safe. However, antiplatelet therapy increases the risk of hospitalization. Despite guideline recommendations, ureteral access sheath use is not associated with anticoagulant/antiplatelet therapy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Hiller SC, Qi J, Leavitt D, et al. Ureteroscopy in Patients Taking Anticoagulant or Antiplatelet Therapy: Practice Patterns and Outcomes in a Surgical Collaborative. J Urol. 2020. PMID: 33035142. doi:10.1097/JU.0000000000001416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。